89bio’s Post

Did you know that most of the current available therapies do not work for every person with cystic fibrosis , particularly leaving behind those whose disease is caused by rare variants? A recent review paper, first-authored and coordinated by Margarida Amaral, group leader of the Cystic Fiborsis Research Lab (at Faculdade de Ciências da Universidade de Lisboa), co-authored by Ines Pankonien (researcher of the same lab) and published in the Journal of Cystic Fibrosis, proposes integrating two approaches, theratyping (using lab-grown cell lines) and theranostics (using patient-derived samples), as way to expand treatment options and establish a more personalized and effective treatment option for more, if not all, people with this disease. Know more by reading this #BioISIDigest: https://bioisi.pt/news/94 Read the full paper: https://bit.ly/3UepdbX #CysticFibrosis #Theranostics #Theratyping #RareMutations

REGISTER: https://lnkd.in/g2W9bgP8 Join Professor Mike Laffan and an expert panel as they share highlights from the International Society on Thrombosis and Haemostasis 2024 Congress. The discussion will focus on key abstracts in the fields of thrombosis, bleeding, and immunohaematology, along with potential implications for practice.

Wanted to share with my network this interesting article from 360Dx below on a biomarker study that Thermo Fisher Scientific is participating in with the FNIH in the hopes to make strides in the early detection of preeclampsia.

Introducing Dr Michelle Mitchener, Senior Postdoctoral Associate at SMART Antimicrobial Resistance (AMR) interdisciplinary research group! Dedicated to deepening our understanding of AMR and mitigating its far-reaching implications for public health, Dr Mitchener studies the Enterococcus faecalis (E. faecalis) bacterium, a leading cause of hospital-acquired infections. Alongside her colleagues at SMART AMR, she investigates the role of tRNA modifications in protein translation – specifically examining their impact on biofilm formation. By better understanding how bacteria evolve and adapt to resist the drugs designed to destroy them, we can better develop effective strategies to reduce the impact of AMR on public health. Learn more about Michelle's motivations, aspirations, and her journey as a researcher at SMART AMR in the feature below! 🧬🔬 #SMARTAMR #AntimicrobialResistance #ResearchSpotlight #PublicHealth #ScienceJourney #Innovation #ResearcherLife

✨Happy #FluorescenceFriday!✨ Check out this stunning image of an alveolar epithelial #organoid from the lab of Dr. Claudia Loebel, taken in our 3D Assay #Flowchip! Dr. Loebel is researching the use of engineered hydrogels in creating 3D alveolar organoids for #PrecisionMedicine. Her #research is advancing how both chronic and acute pulmonary disease are studied and treated. 💡 Learn more about her intriguing work: https://lnkd.in/g9VHTADj  🔬 Image taken with Yokogawa CV8000 

We’re thrilled to announce that our research, "Imaging and Clinical Manifestations of Hematogenous Dissemination in Melioidosis," is set to be published in 𝗕𝗠𝗖 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗜𝗺𝗮𝗴𝗶𝗻𝗴! Our statistical analysis reveals how combining CT features with clinical variables provides a critical, early-warning tool for detecting blood-borne infectious melioidosis.

Tomorrow - Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models. Developed in collaboration with LifeNet Health, this model offers hormonogenic competence and the capacity to connect mechanistic insights with functional outcomes like thyroid hormone synthesis. Save your spot: https://bit.ly/4d4S4HF

🔬 Exciting Developments in our Research🔬 Thrilled to share the outstanding results from our in vivo study, led by our Chief Scientific Officer James (Jim) Roza, evaluating the efficacy of SophorOx®, a proprietary blend of quercetin and rutin, in combating oxidative stress and inflammation. Click on the below link for the manuscript! Key Findings: 🌿 Significantly reduced oxidative stress markers in exercised rats 🌿 Marked decrease in inflammatory markers compared to exercise alone 🌿 No adverse effects Our team is excited about the potential of SophorOx® as a powerful antioxidant and healthy inflammatory agent. Buoyed by these compelling results, we're also thrilled to share that our human clinical study has been successfully completed, marking a pivotal milestone in validating SophorOx®'s benefits. As we move forward, we're eager to delve into the data from our human clinical study! #Research #Innovation #HealthScience #Antioxidant #Inflammation #SophorOx #botanicalinnovation

After the in vitro study, this work also demonstrates the unique characteristics of SophorOx in reducing oxidative stress and inflammation. Layn Natural Ingredients keeps on sharing its knowledge of botanical extracts, innovating with new solutions supported by scientific studies. Silvia, which applications would you recommend for SophorOx?

Last week at the 27th Annual International Congress on Hematologic Malignancies, we presented data from our study in lower-risk myelodysplastic syndromes (#MDS). These data are encores originally presented at #ASH23. See the full poster here: https://lnkd.in/drRUJenK   #WinterHeme24